Skip to main content
Premium Trial:

Request an Annual Quote

Robert Friel, John Roush, Martina Bielefeld-Sévigny, George Adam, Arnold Levine, William Longfield, Eric Setzer, Gary Boch, Jim Sheridan, John Elling, Robert Corn

As part of a realignment of its business into two segments — Human Health and Environmental Health — PerkinElmer said this week that Robert Friel, president and CEO, will lead the Human Health business on an interim basis and John Roush, who currently leads the company’s Optoelectronics business, will lead the Environmental Health division.
The realignment will go into effect on Jan. 1, 2009.
Separately, the company announced that it has appointed Martina Bielefeld-Sévigny to serve as vice president and general manager of drug discovery and research reagents. Bielefeld-Sévigny previously was director of molecular pharmacology in PerkinElmer’s Bio-discovery reagents business, and she led the company’s Center of Excellence in Montreal. She also previously served as director of process development at DSM Biologics, and she worked at Pharmacia Biotech.

Invitrogen has added three members from merger partner Applied Biosystems’ board of directors to serve on the board of the new company, which will be called Life Technologies. These directors include George Adam, chairman of Recondo Technology; Arnold Levine, a professor at the Institute for Advanced Study; and William Longfield, a retired chairman and chief executive officer of CR Bard.

Expression Analysis has hired Eric Setzer to be chief financial officer, and it has named Gary Boch senior director of sales. Seltzer previously was chief financial officer at Kolis Scientific, and Boch was national director of industrial markets at Amaxa.

Jim Sheridan will succeed John Elling as CEO and president of Integrated Genomics. Elling will continue to serve as chairman of the company’s board of directors. Sheridan previously was vice president of commercial operations at High-Throughput Genomics, and he served in other senior roles at PerkinElmer Life and Analytical Sciences, Beckman Coulter, Genomica, and Monsanto.

Robert Corn has been named to the scientific advisory board of Quanterix, the Cambridge, Mass.-based start up said this week.
Corn is a professor in the departments of chemistry and biomedical engineering at the University of California, Irvine. His primary research areas include the development of new methods for detecting binding of biomolecules to surfaces and chemical modification strategies to control specific and non-specific adsorption of biopolymers to a variety of surfaces, Quanterix said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.